The “ever-vaccinated” stock–flow bias in adult RSV vaccine policy evaluation: A methodological caution and a flow-based remedy

= .008 post hoc, did not persist); these underpowered analyses are illustrative only, not identified for the policy effect. To our knowledge, this is the first portable flow-metric operationalization for survey and registry data, released as open code. Registry data exploratorily show the stock metric can obscure equity monitoring (Gini 0.210→0.202; range 39.7→43.5 pp; not significant). As a mid-season snapshot, these figures are an upper bound on the end-of-season value; the conclusion that coverage is dominated by prior-season stock holds through the season. RSV policy evaluation should pre-specify current-season flow as the primary outcome and report the stock share as a strongly recommended diagnostic.

Authors

Publication Details

Journal
Human Vaccines & Immunotherapeutics
Published
2026-11-12
DOI
https://doi.org/10.1080/21645515.2026.2755223
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The “ever-vaccinated” stock–flow bias in adult RSV vaccine policy evaluation: A methodological caution and a flow-based remedy

Ling Chen, Weiping Deng
Human Vaccines & Immunotherapeutics
Respiratory viral infections research
article

The “ever-vaccinated” stock–flow bias in adult RSV vaccine policy evaluation: A methodological caution and a flow-based remedy

Ling Chen, Weiping Deng
article en

Abstract

= .008 post hoc, did not persist); these underpowered analyses are illustrative only, not identified for the policy effect. To our knowledge, this is the first portable flow-metric operationalization for survey and registry data, released as open code. Registry data exploratorily show the stock metric can obscure equity monitoring (Gini 0.210→0.202; range 39.7→43.5 pp; not significant). As a mid-season snapshot, these figures are an upper bound on the end-of-season value; the conclusion that coverage is dominated by prior-season stock holds through the season. RSV policy evaluation should pre-specify current-season flow as the primary outcome and report the stock share as a strongly recommended diagnostic.

Human Vaccines & ImmunotherapeuticsVol. 22(1)
Good health and well-being
Respiratory viral infections research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon